Subscribe to Supplier

Subscribe to Supplier

.

Bachem case study demonstrates enzymatic ligation route to multi-kilogram siRNA manufacturing

news-releasesBachem AG
November 18th 2026

Bubendorf, Switzerland – Bachem, the leading CDMO, has published a new case study with Codexis showing how small interfering RNA (siRNA) can be manufactured by synthesizing short RNA fragments and joining them through enzymatic ligation. Beyond the case study, Bachem has established the ligation process in Switzerland and demonstrated it in multi-kilogram GMP manufacture.

In the process, multiple fragments for each siRNA strand are annealed according to their base complementarity, and an engineered double-stranded RNA (dsRNA) ligase joins them to generate the siRNA. Short fragments have inherently higher yield and purity than full-length strands, so the approach offers the prospect of higher yields, increased purity and a reduced purification burden.

Limits of conventional synthesis

Demand for siRNA therapeutics is expected to grow substantially as development expands beyond rare diseases into high-prevalence indications such as dyslipidemia, hypertension, obesity and cardiometabolic disorders.

Flow-through solid-phase oligonucleotide synthesis (FT-SPOS) is well established, but full-length yield falls as strand length increases: even at 98–99% coupling efficiency, a 23-nucleotide siRNA guide strand yields only 65–80% full-length product. Batch sizes are typically limited to about 2 mol, or 10–20 kg, per synthesis train, so larger demand is met with more batches rather than larger ones.

Fragment design and ligation

Using the commercial siRNA vutrisiran as a model, the case study combines Codexis’ engineered dsRNA ligases and its computational fragment design approach, FragLink™, with Bachem’s fragment synthesis and scale-up expertise.

All three top-ranked fragment designs achieved greater than 94% ligation efficiency for both strands within four hours. At a 3-fold higher substrate loading, ligation efficiency reached 97% or higher at low enzyme loading, and no novel impurities arose from the ligation itself.

Scale-up and product quality

Bachem made the fragments using both FT-SPOS and its stirred-bed (SBT)-SPOS technology, then scaled the ligation 100-fold across multiple reactor formats with nearly identical conversion profiles. Residual enzyme was reduced below the limit of detection, and the duplex was purified continuously by Multicolumn Countercurrent Solvent Gradient Purification (MCSGP).

The resulting vutrisiran showed purities and impurity profiles comparable to material made by conventional linear FT-SPOS.

The paper explains:

  • Why conventional FT-SPOS limits yield, purity and batch size as demand for siRNA grows
  • How FragLink™ fragment design increases the likelihood of identifying a successful ligation strategy 4- to 6-fold compared with randomly selected designs, based on internal validation data
  • How ligation reached 97% or higher efficiency at 6 mM (98.1 g/L) RNA loading with 0.5 g ligase/kg RNA
  • How higher solid support loading (up to 450 µmol/g) and fewer phosphoramidite equivalents (2.0 to 1.4 eq) made fragment synthesis more economical
  • How residual enzyme was removed and the duplex purified by ion exchange chromatography and MCSGP

The case study can be downloaded from the Bachem Knowledge Hub via the link under Resources.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

For further information, see www.bachem.com

Resources

See Case study: Scale siRNA manufacturing efficiently via a fragment and enzymatic ligation approach to access the full technical paper.
Click on Bachems News to see latest News & Events.

CASE STUDY

Scale siRNA manufacturing efficiently via a fragment and enzymatic ligation approach

FREE DOWNLOAD
Bachem case study demonstrates enzymatic ligation route to multi-kilogram siRNA manufacturing

Bachem AG

Contact Information
Address: Hauptstrasse 144, 4416, Bubendorf, Switzerland
Telephone No: +41 58 595 2021

Contact Bachem AG

Simply fill out the form below to contact Bachem AG now.

Send Bachem AG a Message